C. Michael Gibson

Active 1967–2026

Also published as
C Michael Gibson
309
Papers
76,541
Citations
129
h-index
294
i10-index

Citations

Citations per year for C. Michael Gibson1944: 1 citations1952: 1 citations1970: 1 citations1976: 1 citations1983: 1 citations1991: 1 citations1993: 22 citations1994: 31 citations1995: 40 citations1996: 47 citations1997: 41 citations1998: 74 citations1999: 58 citations2000: 93 citations2001: 124 citations2002: 136 citations2003: 202 citations2004: 268 citations2005: 271 citations2006: 254 citations2007: 296 citations2008: 301 citations2009: 346 citations2010: 403 citations2011: 410 citations2012: 428 citations2013: 377 citations2014: 411 citations2015: 359 citations2016: 304 citations2017: 419 citations2018: 390 citations2019: 1,456 citations2020: 2,372 citations2021: 2,022 citations2022: 1,466 citations2023: 1,055 citations2024: 1,780 citations2025: 829 citations2026: 46 citations1945–1951: no citations, so these years are not shown1953–1969: no citations, so these years are not shown1971–1975: no citations, so these years are not shown1977–1982: no citations, so these years are not shown1984–1990: no citations, so these years are not shown1992: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,470 citing papers, 22.2% of this breakdownUnited Kingdom: 1,917 citing papers, 7.8% of this breakdownItaly: 1,706 citing papers, 6.9% of this breakdownGermany: 1,421 citing papers, 5.8% of this breakdownCanada: 1,171 citing papers, 4.7% of this breakdownChina: 1,147 citing papers, 4.7% of this breakdownFrance: 1,013 citing papers, 4.1% of this breakdownNetherlands: 945 citing papers, 3.8% of this breakdownSpain: 741 citing papers, 3% of this breakdownSwitzerland: 644 citing papers, 2.6% of this breakdownJapan: 643 citing papers, 2.6% of this breakdownAustralia: 626 citing papers, 2.5% of this breakdown
0%22.2%Other 29.3%

Fields

  • Medicine87.9%
  • Biochemistry, Genetics and Molecular Biology4.7%
  • Engineering1.4%
  • Immunology and Microbiology1.4%
  • Nursing1.2%
  • Computer Science0.5%
  • Other2.9%

Topics

  • Acute Myocardial Infarction Research7.9%
  • Antiplatelet Therapy and Cardiovascular Diseases6.1%
  • Coronary Interventions and Diagnostics5.9%
  • Atrial Fibrillation Management and Outcomes4.4%
  • Cardiac Imaging and Diagnostics4.3%
  • Venous Thromboembolism Diagnosis and Management3.6%
  • Other67.8%

Coauthors

All papers

Open in search
  1. Standardized Bleeding Definitions for Cardiovascular Clinical Trials

    Authors: , , , , , , , , , , , , , , , , , , , - Circulation 2011 cited by 4,423

  2. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

    Authors: , , , , , , , , , , , , , - New England Journal of Medicine 2007 cited by 6,747

  3. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paul Burton, Laura Mauri, Christopher M. O’Connor, Marc A. Pfeffer, Hung Hung, Norman Stockbridge, Bernard Chaitman, Robert J. Temple - Circulation 2018 cited by 713

  4. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 798

  5. Ticagrelor with or without Aspirin in High-Risk Patients after PCI

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Gabríel Steg, Giora Weisz, Bernhard Witzenbichler, Yaling Han, Stuart Pocock, C. Michael Gibson - New England Journal of Medicine 2019 cited by 1,000

  6. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ute Windhoevel, Robert W. Yeh, Mitchell W. Krucoff, Marie-Claude Morice - Circulation 2019 cited by 796

  7. Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2014 cited by 1,036

  8. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 1,557

  9. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 946

  10. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ute Windhoevel, Robert W. Yeh, Mitchell W. Krucoff, Marie-Claude Morice - European Heart Journal 2019 cited by 572

  11. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Gabríel Steg, Robert F. Storey, Jurriën M. ten Berg, Marco Valgimigli, Pascal Vranckx, Hirotoshi Watanabe, Stephan Windecker, Patrick W. Serruys, Robert W. Yeh, Marie‐Claude Morice, Dominick J. Angiolillo - Circulation 2023 cited by 165

  12. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kenneth W. Mahaffey, Stephen J. Nicholls, Stuart Pocock, Roxana Mehran, Robert A. Harrington - New England Journal of Medicine 2024 cited by 122

  13. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2011 cited by 1,887

  14. ST-segment elevation myocardial infarction

    Authors: , , , , , , , , , , , , , , , , - Nature Reviews Disease Primers 2019 cited by 423

  15. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John W. Eikelboom, Ido Weinberg, Sam Schulman, Marc Carrier, Gregory Piazza, Joshua A. Beckman, Philippe Gabríel Steg, Gregg W. Stone, Stephan Rosenkranz, Samuel Z. Goldhaber, Sahil A. Parikh, Manuel Monréal, Harlan M. Krumholz, Stavros Konstantinides, Jeffrey I. Weitz, Gregory Y.H. Lip - Journal of the American College of Cardiology 2020 cited by 2,939

  16. Outcomes in High-Risk Pulmonary Embolism Patients Undergoing FlowTriever Mechanical Thrombectomy or Other Contemporary Therapies: Results From the FLAME Study

    Authors: , , , , , , , , , , , , , , - Circulation Cardiovascular Interventions 2023 cited by 170

  17. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paul Burton, Laura Mauri, Christopher M. O’Connor, Marc A. Pfeffer, Hung Hung, Norman Stockbridge, Bernard Chaitman, Robert J. Temple, Heather D. Fitter, Kachikwu Illoh, Kenneth J. Cavanaugh, Benjamin M. Scirica, Ilan Irony, Rachel E. Brown Kichline, Jonathan G. Levine, Anna Park, Leonard Sacks, Ana Szarfman, Ellis F. Unger, Lori Ann Wachter, Bram Zuckerman, Yale Mitchel, Douglas Peddicord, Thomas Shook, Bron Kisler, Charles L. Jaffe, Rhonda Bartley, David L. DeMets, MariJo Mencini, Cheri Janning, Steve Bai, John Lawrence, Ralph B. D’Agostino, Stuart Pocock - Journal of the American College of Cardiology 2018 cited by 322

  18. TIMI Frame Count

    Authors: , , , , , , , , , , - Circulation 1996 cited by 1,856

  19. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Majed A. Refaai, M. Rehman, Alvin H. Schmaier, E. Schwarz, William C. Shillinglaw, Michael Spohn, Tohru Takata, Arvind Venkat, James Welker, Ian J. Welsby, Joanna Y. Wilson, L. Van Keer, Franck Verschuren, Mark Blostein, John W. Eikelboom, Katharina Althaus, Jörg Berrouschot, Gary Braun, T. Doeppner, Rainer Dziewas, Sabine Genth‐Zotz, P. Greinacher, F. Hamann, Frank Hanses, W. Heide, Bernd Kallmuenzer, Pawel Kermer, Sven Poli, Georg Royl, Sebastian Schellong, Steffen Schnupp, Jürgen Schwarze, Claudia Spies, Götz Thomalla, Matthias von Mering, Karin Weißenborn, Frank A. Wollenweber, Christoph Gumbinger, Ulrich Jaschinski, M. Maschke, H-C. Mochmann, Waltraud Pfeilschifter, C. Pohlmann, Ralf Zahn, Pierre Bouzat, Jeannot Schmidt, Cristina Díez Vallejo, Bernard Floccard, Michiel Coppens, Sanne van Wissen, Eduardo Arellano‐Rodrigo, Ermengol Vallès, Raza Alikhan, Kerry J. Breen, Richard Hall, Mark Crowther, Pierre Albaladejo, Alexander T. Cohen, Andrew M. Demchuk, Jeannot Schmidt, D. George Wyse, D.A. Garcia, M.H. Prins, Juliet Nakamya, H.R. Büller, K. W. Mahaffey, John H. Alexander, John A. Cairns, R G Hart, Cameron D. Joyner and 12 more - Circulation 2023 cited by 152

  20. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials

    Authors: , , , , , , , , , , , , , , , - European Heart Journal 2021 cited by 150

  21. Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , William J. Nicholson, Yoshinobu Onuma, Georgios Sianos, Satoru Sumitsuji, Etsuo Tsuchikane, Renu Virmani, Simon Walsh, Gerald S. Werner, Masahisa Yamane, Gregg W. Stone, Stéphane Rinfret, Gregg W. Stone - Circulation 2021 cited by 290

  22. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 cited by 825

  23. Saphenous vein grafts in contemporary coronary artery bypass graft surgery

    Authors: , , , , , , , , , , - Nature Reviews Cardiology 2019 cited by 260

  24. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - BMJ 2021 cited by 255